Bank of Montreal Can lowered its stake in Retrophin Inc (NASDAQ:RTRX) by 1.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 173,839 shares of the biopharmaceutical company’s stock after selling 2,505 shares during the period. Bank of Montreal Can’s holdings in Retrophin were worth $3,934,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY increased its holdings in shares of Retrophin by 318.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,785 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 10,491 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Retrophin during the 1st quarter valued at $327,000. Legal & General Group Plc raised its stake in Retrophin by 17.2% during the 4th quarter. Legal & General Group Plc now owns 15,866 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 2,325 shares during the period. Ontario Teachers Pension Plan Board acquired a new stake in Retrophin during the 4th quarter valued at $420,000. Finally, Virginia Retirement Systems ET AL raised its stake in Retrophin by 9.6% during the 1st quarter. Virginia Retirement Systems ET AL now owns 20,500 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 1,800 shares during the period.
In other news, insider William E. Rote sold 2,500 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $21.48, for a total value of $53,700.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 5,000 shares of company stock worth $107,400 over the last ninety days. 4.32% of the stock is currently owned by company insiders.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.41). Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The firm had revenue of $39.57 million for the quarter, compared to analyst estimates of $41.40 million. During the same period last year, the firm earned ($0.14) earnings per share. Retrophin’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Retrophin Inc will post -2.47 earnings per share for the current fiscal year.
Several analysts have issued reports on the stock. ValuEngine downgraded shares of Retrophin from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Svb Leerink reissued an “outperform” rating on shares of Retrophin in a research note on Tuesday, February 26th. BidaskClub downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Thursday, April 4th. Barclays assumed coverage on shares of Retrophin in a research note on Monday, April 22nd. They set an “overweight” rating and a $36.00 target price on the stock. Finally, Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $45.67.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2019/05/14/bank-of-montreal-can-reduces-holdings-in-retrophin-inc-rtrx.html.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Story: Google Finance Portfolio
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.